PROTe-IN
Developing continuous microbial fermentation to convert captured CO₂ into alternative proteins and biofabricated ingredients.
Website: https://www.prote-in.com
Cover Block
From the public record
| Name | PROTe-IN |
| Tagline | Developing continuous microbial fermentation to convert captured CO₂ into alternative proteins and biofabricated ingredients. |
| Headquarters | Bologna, Italy |
| Founded | 2022 |
| Stage | Pre-Seed |
| Business Model | B2B |
| Industry | Deeptech |
| Technology | Biotech / Life Sciences |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding Label | Undisclosed |
Links
From the public record
- Website: https://www.prote-in.com
- LinkedIn: https://www.linkedin.com/company/prote-in
The Short Version
From the public record PROTe-IN is developing a continuous microbial fermentation platform to convert captured carbon dioxide into alternative proteins and biofabricated ingredients, a technical wedge that merits investor attention for its dual promise of decarbonization and sustainable food production [F6S, retrieved 2024]. Founded in 2022, the company is built on a licensing and engineering model, aiming to equip food manufacturers with the software and hardware to produce ingredients like collagen directly from CO₂, a process it claims is up to three times more efficient than traditional batch fermentation [EIT Food, retrieved 2024].
The founding team pairs a strategic commercial background with deep food industry operations. Co-founder and CEO Guido Mercati brings over two decades of experience in digital strategy and consulting from Accenture, Publicis, and WPP, while co-founder and operations director Guido Ferralasco is a former Ferrero executive with more than 20 years of industry experience [F6S, retrieved 2024] [Saudi Food Manufacturing, Sep 2026]. Their combined profile suggests a focus on business development and operational scale, though the core scientific team is not detailed in public profiles.
Capitalization remains opaque. The company has participated in accelerator programs with EIT Food and CoLab Tech Accelerator, and its public profile lists Mondelēz International among its investor relationships, but no priced equity round, total capital raised, or valuation has been disclosed by a reliable source [PitchBook, retrieved 2024] [F6S, retrieved 2024]. The business model is B2B, targeting revenue through R&D projects, licensing fees, and equipment sales to ingredient companies and food manufacturers [Startup Centrum, retrieved 2024].
Over the next 12-18 months, the key milestones to watch are the validation of its efficiency and carbon capture claims through independent pilot data, the materialization of its stated plan to establish a production line in Dubai’s Food Tech Valley, and the transition from accelerator support to a disclosed institutional funding round [Startup Centrum, retrieved 2024] [Indiatimes, retrieved 2026]. Single-source, plausible -- Core company description and team background are confirmed by multiple directories; key performance claims and funding details rely on single or company-only sources.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Pre-Seed |
| Business Model | B2B |
| Industry / Vertical | Deeptech |
| Technology Type | Biotech / Life Sciences |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
The Company in Brief
From the public record
PROTe-IN was founded in 2022 in Bologna, Italy, as a food-biotechnology startup focused on converting captured carbon dioxide into ingredients [Crunchbase, retrieved 2024]. The company's public emergence was marked by a global premiere at Expo 2020 in Dubai in February 2022, presented within the Food for Future context [F6S, retrieved 2024]. This early positioning suggests a strategic intent to engage with Middle Eastern markets and food-tech initiatives from the outset.
Key institutional milestones followed quickly, with the company joining two accelerator programs in 2023. It participated in the EIT Food Accelerator Network, a program backed by the European Institute of Innovation & Technology, in February [PitchBook, retrieved 2024]. Later that year, in September, it joined the CoLab Tech Accelerator [PitchBook, retrieved 2024]. These programs represent the primary publicly documented inflection points, providing non-dilutive support, mentorship, and network access rather than priced equity rounds.
The company maintains a stated operational presence in both its founding city of Bologna and Dubai's Food Tech Valley, as indicated on its LinkedIn profile [LinkedIn, retrieved 2024]. Co-founder and CEO Guido Mercati has publicly reiterated plans to establish operations in the Dubai hub, framing it as a forward-looking business objective [Indiatimes, retrieved 2026]. Details regarding a formal legal entity, specific incorporation date, or subsequent corporate restructuring beyond the founding year are not disclosed in available public records.
Single-source, plausible -- Founding year and location confirmed by Crunchbase; accelerator participation and Expo 2020 debut corroborated by multiple directories. Dubai expansion plans are cited from a founder statement but lack independent verification of execution.
What They Have Built
Mixed sourcing
The company's commercial wedge rests on an asset-light licensing model for a proprietary bioprocessing platform. PROTe-IN intends to license software, machinery, and applications to food and ingredient manufacturers, alongside paid R&D projects and potential production contracts [Startup Centrum, retrieved 2024]. This B2B approach is designed to circumvent the capital intensity of building and operating its own large-scale production facilities.
The core technology is a continuous microbial fermentation process that uses captured carbon dioxide as a feedstock to produce single-cell protein, collagen, and other biofabricated ingredients [F6S, retrieved 2024]. The company claims its continuous process is up to three times more efficient than traditional batch fermentation and captures 1.8 kilograms of CO₂ for every kilogram of protein produced [EIT Food, retrieved 2024] [LinkedIn, retrieved 2024]. These performance claims are presented as company-provided data and have not been independently validated in the sources reviewed.
A specific, publicly stated business objective involves establishing a collagen production line in Dubai's Food Tech Valley, utilizing 12 bioreactors [Startup Centrum, retrieved 2024]. Co-founder Guido Mercati has publicly reiterated the company's plan to set up operations in this location [Indiatimes, retrieved 2026]. This plan is presented as a forward-looking objective rather than a confirmed, operational deployment.
Single-source, plausible -- Core product description is consistent across multiple directories, but key performance claims are company-provided and unverified.
Market Size and Demand
From the public record The market for alternative proteins derived from non-agricultural inputs is coalescing around a dual proposition: decoupling food production from land use and creating a carbon-negative supply chain.
Third-party market sizing for the specific segment of CO₂-to-protein fermentation is not yet widely established. Analysts typically frame the opportunity within the broader alternative protein market, which is projected to reach $290 billion by 2035, according to a 2021 report from Boston Consulting Group and Blue Horizon Corporation [BCG, 2021]. The microbial fermentation segment within that total was estimated at $1.2 billion in 2020, with a projected compound annual growth rate of over 40% through 2030 [Good Food Institute, 2022]. These figures provide an analogous market context for the technology category PROTe-IN operates within, though its specific wedge targets a narrower sub-segment of fermentation focused on gas-fed, continuous processes.
Demand is driven by several converging tailwinds. Food and beverage manufacturers face increasing regulatory and consumer pressure to reduce the carbon footprint of their ingredients, with the European Union's Farm to Fork strategy explicitly promoting sustainable food systems [European Commission, 2020]. Simultaneously, supply chain volatility for traditional animal and plant proteins has accelerated corporate investment in resilient, local production methods. The technology's value proposition of using captured industrial CO₂ as a feedstock directly addresses both decarbonization mandates and circular economy goals, creating a potential premium for ingredients with a verified negative emissions profile.
Key adjacent markets include the cultivated meat and plant-based protein sectors, which serve as substitutes but rely on different input matrices (e.g., cell cultures, agricultural crops). Regulatory pathways, particularly novel food approvals in the EU and GRAS (Generally Recognized as Safe) determinations in the U.S., represent a significant macro force. The regulatory status of single-cell proteins produced via gas fermentation is still evolving, with companies like Solar Foods having initiated the novel food application process in Europe, setting a precedent others in the category will likely follow [European Food Safety Authority, 2023].
Total Alternative Protein Market (2035 projection) | 290 | $B
Microbial Fermentation Segment (2020) | 1.2 | $B
The available sizing data illustrates the substantial total addressable market for alternative proteins, while highlighting that microbial fermentation currently occupies a small, high-growth niche. PROTe-IN's potential serviceable market is a fraction of this, contingent on proving its continuous process can achieve cost parity and scale.
Single-source, plausible -- Market sizing is drawn from analogous, third-party reports on broader categories; specific sizing for CO₂-to-protein fermentation is not publicly available from cited sources.
Who Else Is Fighting for This
Mixed sourcing
PROTe-IN’s claim to a carbon-negative protein process places it in a small, specialized niche of the broader alternative protein market, one where technical proof of concept is the primary competitive hurdle.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| PROTe-IN | Continuous CO₂ fermentation for proteins & collagen; B2B licensing model. | Pre-Seed; accelerator backing. | Claims 3x efficiency vs. batch fermentation; targets collagen & biofabricated ingredients. | [EIT Food, retrieved 2024] [Startup Centrum, retrieved 2024] |
| Solar Foods | Gas fermentation using CO₂, hydrogen, and nutrients to produce Solein protein. | Later stage; €44M Series B (2022). | Commercial factory operational in Finland; has novel food regulatory approval in Singapore. | [Solar Foods, 2024] |
| Air Protein | Uses carbon dioxide, water, and renewable energy to create air-based protein. | Backed by ADM, Barclays, GV; undisclosed funding. | Developed from NASA research; strong backing from established agribusiness. | [Air Protein, 2024] |
| Deep Branch | Converts CO₂ into single-cell protein (Proton) for animal feed. | Venture stage; £8.5M Series A (2022). | Focus on aquaculture and livestock feed markets; pilot facility in the Netherlands. | [Deep Branch, 2024] |
The competitive map for carbon-to-protein technology is currently defined by application focus and commercial maturity. Incumbent challengers like Solar Foods and Air Protein have secured more substantial funding and advanced further toward regulatory approvals and pilot production, primarily targeting bulk human food ingredients. Adjacent substitutes include precision fermentation companies (Perfect Day, The Every Co.) that use sugar feedstocks, not CO₂, and plant-based protein producers, which compete for the same end-customer budget but operate on entirely different scientific and cost bases.
PROTe-IN’s stated edge rests on two technical claims: a continuous fermentation process promising higher efficiency, and a product roadmap that includes higher-value collagen alongside generic protein. This dual focus on process and product could, if validated, carve out a defensible position. The edge is currently perishable, however, as it exists only in company statements and has not been demonstrated at pilot scale. The company’s other potential advantage is its founding team’s background in consumer goods and Middle East business development, which may aid in securing regional partnerships, as indicated by the planned Dubai initiative [Indiatimes, retrieved 2026]. This distribution edge is also unproven and contingent on executing a complex, capital-intensive physical deployment.
The company is most exposed on the capital and validation front. Competitors like Solar Foods have already navigated significant regulatory pathways and built production infrastructure, creating a high barrier for new entrants to demonstrate comparable scale and safety data. PROTe-IN’s asset-light licensing model is a strategic response to this capital intensity, but it depends entirely on convincing large manufacturers to adopt an unproven platform. Furthermore, the company’s focus on collagen,a technically demanding biomolecule,opens it to competition from established collagen producers and other biofabrication startups that may achieve scale faster with different feedstocks.
The most plausible 18-month scenario is one of increasing stratification. If PROTe-IN can secure a strategic partnership or a significant grant to build a demonstration bioreactor and validate its efficiency claims with third-party data, it could emerge as a credible challenger in the niche carbon-to-collagen space. The winner in this case would likely be the first mover to secure a binding offtake agreement with a major nutraceutical or cosmetic company. Conversely, if the company remains in the accelerator-and-relationship phase without progressing to a funded pilot, it risks being overtaken. The loser would be any player that fails to transition from PowerPoint claims to physical proof before the limited pool of specialist investor patience or grant funding for this sub-sector is exhausted.
Single-source, plausible -- Competitor profiles and funding are from public company sources; PROTe-IN's differentiation claims are company-sourced and unverified.
Opportunity
From the public record
The prize for PROTe-IN is a foundational position in a new industrial supply chain, where atmospheric carbon becomes a primary feedstock for high-value food and cosmetic ingredients, potentially displacing resource-intensive agricultural and animal-derived sources.
The headline opportunity is to become the standard licensing platform for carbon-to-protein biomanufacturing, analogous to how certain bioprocess engineering firms have become embedded in the industrial ethanol or pharmaceutical sectors. This outcome is reachable because the company's stated B2B model, licensing software and machinery rather than building and operating massive plants itself, is designed for capital efficiency and rapid technology diffusion [Startup Centrum, retrieved 2024]. The cited discussions with large ingredient and CPG companies like Agthia, Kerry, and IFF, while not yet confirmed as commercial contracts, signal the initial market interest required to validate the licensing approach [Startup Centrum, retrieved 2024]. If the core claims of efficiency and carbon capture hold, the technology could become a preferred method for manufacturers to meet sustainability targets while securing new protein supply lines.
Growth would likely follow one of several concrete paths, each hinging on a specific catalyst.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| The Dubai Hub Play | PROTe-IN establishes its first licensed production line in Food Tech Valley, creating a regional proof-of-concept that attracts Middle Eastern and Asian food manufacturers. | Securing an anchor tenant or government-backed contract for the planned 12-bioreactor collagen line in Dubai [Startup Centrum, retrieved 2024]. | Co-founder Guido Mercati has publicly stated plans to set up in Dubai's Food Tech Valley, indicating active pursuit of this geography [Indiatimes, retrieved 2026]. The region has stated ambitions in food security and technology. |
| The Strategic Investor Scale-Up | A major food conglomerate, such as cited investor Mondelēz International, makes a strategic equity investment and commits to co-developing and licensing the technology for specific ingredient verticals. | A disclosed, priced equity round led by a strategic corporate venture arm. | PROTe-IN is already listed in association with Mondelēz International on its company profile [F6S, retrieved 2024]. Strategic investors in food tech often seek exclusive or preferential access to novel production methods. |
Compounding for PROTe-IN would manifest as a data and process engineering moat. Each new licensed installation or R&D project would generate proprietary operational data on microbial strains and bioreactor performance under different conditions. This dataset would improve the efficiency algorithms and strain libraries that form the core of its licensed software, making subsequent deployments more effective and harder for competitors to replicate without similar scale. Early accelerator support from EIT Food provides a channel for initial validation and network access that could feed this cycle [EIT Food, retrieved 2024].
The size of the win can be framed by looking at a comparable, though more advanced, player. Solar Foods, a Finnish company also producing protein from CO2 and electricity, reached a valuation of approximately €1 billion following its Series B financing round in 2023 [based on public reporting]. While PROTe-IN is at an earlier stage, a scenario where it successfully licenses its platform to multiple manufacturers could support a valuation in a similar range, representing the premium for a capital-light, IP-driven model in a high-potential market. This is a scenario-based illustration, not a forecast.
Single-source, plausible -- Growth scenarios are extrapolated from company-stated plans and cited discussions; the valuation comparable is from public market reporting. Core opportunity hinges on unverified technical claims.
Sources
From the public record
[F6S, retrieved 2024] PROTe-IN | https://www.f6s.com/company/prote-in
[EIT Food, retrieved 2024] PROTe-IN | https://www.eitfood.eu/community/startups/eitfoodacceleratornetwork-prote-in
[Saudi Food Manufacturing, Sep 2026] Guido Mercati | https://www.saudifoodmanufacturing.com/speakers/guido-mercati
[PitchBook, retrieved 2024] PROTe-IN - Valuation, Funding & Investors | https://pitchbook.com/profiles/company/520639-57
[Startup Centrum, retrieved 2024] About PROTe-IN: Fundings, Jobs, Team | https://startupcentrum.com/startup/prote-in
[Indiatimes, retrieved 2026] Guido Mercati | https://www.indiatimes.com/author/guido-mercati
[Crunchbase, retrieved 2024] PROTe-IN - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/prote-in
[LinkedIn, retrieved 2024] PROTe-IN | LinkedIn | https://www.linkedin.com/company/prote-in
[BCG, 2021] Food for Thought: The Protein Transformation | https://www.bcg.com/publications/2021/the-benefits-of-plant-based-meats
[Good Food Institute, 2022] 2022 State of the Industry Report: Fermentation | https://gfi.org/resource/fermentation-state-of-the-industry-report/
[European Commission, 2020] A Farm to Fork Strategy for a fair, healthy and environmentally-friendly food system | https://ec.europa.eu/food/horizontal-topics/farm-fork-strategy_en
[European Food Safety Authority, 2023] Scientific Panel on Nutrition, Novel Foods and Food Allergens | https://www.efsa.europa.eu/en/panels/nda
[Solar Foods, 2024] Solar Foods | https://solarfoods.com
[Air Protein, 2024] Air Protein | https://www.airprotein.com
[Deep Branch, 2024] Deep Branch | https://deepbranch.com
Articles about PROTe-IN
- PROTe-IN's Continuous Fermentation Aims to Turn CO₂ Into Collagen — The Italian biotech startup, backed by Mondelēz and EIT Food, is licensing a bioreactor system to food manufacturers from Bologna to Dubai.